Hepatitis C Main Section
FDA-approved Treatments
Experimental Treatments
Top New Articles

FDA-Approved Combination Therapy
Pegasys + Copegus
(peginterferon alfa-2a + ribavirin)		Roferon A + Ribavirin
(Standard interferon alfa-2a + ribavirin)
PegIntron + Rebetol
(peginterferon alfa-2b + ribavirin)
Intron A + Rebetol
(Standard Interferon alfa-2b + ribavirin)

 

Pegasys + Copegus    peginterferon alfa-2a + Copegus (ribavirin)

PEGASYS Medication Guide
Pegasys Product Information 		Copegus Medication Guide
Copegus Product Information

Articles on Pegasys + Copegus

•
Factors Predicting Relapse in Patients with Genotype 2/3 HCV Treated with Pegylated Interferon plus Ribavirin - 5/06/08
•
Cyclophilin Inhibitor Debio 025 Exhibits Additive Activity against HCV in Combination with Pegylated Interferon - 5/06/08
•
IDEAL Study Finds Higher End-of-treatment Response with Pegasys, but Lower Relapse Rate with PegIntron - 5/02/08
•
Milk Thistle (Silibinin) Shows Potent Antiviral Activity in Hepatitis C Patients Who Are Non-responders to Pegylated Interferon/Ribavirin - 5/02/08
•
R7128 Demonstrates Potent Anti-HCV Activity in Combination with Pegylated Interferon/Ribavirin; Ongoing Trial to be Expanded - 4/29/08
•
Large HCV RNA Decrease Reduces Adverse Clinical Outcomes, but Pegylated Interferon Maintenance Adds Little Benefit (HALT-C) - 4/29/08
•
Pegylated Interferon Maintenance Demonstrates Benefits for Hepatitis C Patients with Portal Hypertension - 4/29/08
•
HCV Polymerase Inhibitor R1626 Produces Good Response with Pegylated Interferon/Ribavirin and Has High Barrier to Resistance - 4/29/08
•
Telaprevir plus Pegylated Interferon and Ribavirin Allows Shorter Therapy for Patients with Genotype 1 HCV - 4/29/08
•
Use of Different Pegylated Interferon/Ribavirin Regimens after Rapid Virological Response Does Not Affect Sustained Response Rate - 3/18/08
•
Pegylated Interferon plus Ribavirin for Patients with HCV-related Liver Cirrhosis - 3/11/08
•
Duration of Pegylated Interferon plus Ribavirin for HCV Genotypes 2 and 3 - 1/29/08
•
Hepatology Expert Discusses PegIntron vs Pegasys IDEAL Study Findings - 1/18/08
•
Growth Hormone Deficiency Common in Hepatitis C Patients, but Improves with Interferon-based Treatment - 1/08/08
•
Pegylated Interferon plus Ribavirin in the Treatment of Chronic Hepatitis C Genotype 4 - 1/08/08
•
Duration of Pegylated Interferon plus Ribavirin May Be Tailored Based on Early Response - 1/04/08
•
Eltrombopag Raises Platelet Counts, Enabling Initiation of Interferon-based Therapy for Hepatitis C - 1/04/08
•
Experimental Polymerase Inhibitor HCV-796 is Safe and Effective in Combination with PegIntron or Pegasys - 12/07/07
•
Depression Due to Treatment with Pegylated Interferon plus Ribavirin May Be Under-diagnosed by Clinicians - 11/30/07
•
How Effective Is Pegylated Interferon plus Ribavirin for HCV Genotype 1 Patients Over Age 50? - 11/30/07
•
Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin for Patients with HBV and HCV Coinfection - 11/30/07
•
Prophylaxis with Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin vs No Prophylaxis after Liver Transplantation - 11/27/07
•
Is Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin Superior to High-dose Consensus Interferon (Infergen) plus Ribavirin? - 11/27/07
•
Induction with High-dose Pegylated Interferon alfa-2a (Pegasys) Is More Effective than Standard Dosing for Achieving Rapid and Early Virological Response: The CHARIOT Study - 11/20/07
•
Is Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin Superior to High-dose Consensus Interferon (Infergen) plus Ribavirin?
•
Prophylaxis with Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin vs No Prophylaxis after Liver Transplantation
•
Induction with High-dose Pegylated Interferon alfa-2a (Pegasys) Is More Effective than Standard Dosing for Achieving Rapid and Early Virological Response: The CHARIOT Study - 11/20/07
•
HALT-C Trial Shows Minimal Long-term Benefit of Pegylated Interferon Alfa-2a (Pegasys) Maintenance Therapy in Patients with Chronic Hepatitis C - 11/16/07
•
Interim Data Show Nitazoxanide (Alinia) Improves Anti-HCV Activity When Added to Pegylated Interferon plus Ribavirin - 11/13/07
•
Combination Therapy with HCV Protease Inhibitor Telaprevir (VX-950) plus Pegylated Interferon and Ribavirin Produces Sustained Response in 61% of Genotype 1 Patients - 11/06/07
•
Experimental Roche Polymerase Inhibitor R1626 Shows Robust Synergistic Effect in Combination with Pegylated Interferon with or without Ribavirin - 11/06/07
•
Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin in Non-responders to Pegylated Interferon Alfa-2b (PegIntron) plus Ribavirin: Final Results of the REPEAT Trial - 11/06/07
•
Assessment of Viral Kinetics Helps Predict Response to Treatment with Pegylated Interferon Alfa plus Ribavirin in Chronic Hepatitis C Patients - 11/06/07
•
Does Attainment of Sustained Virologic Response (SVR) from Treatment of HCV Constitute a Cure?   - 5/20/07
•

How Ideal Is the IDEAL Trial?

PegIntron + Rebetol    peginterferon alfa-2b + Rebetol (ribavirin)

PEG-INTRON® Prescribing Information REBETOL® Prescribing Information

Articles on PegIntron + Rebetol

•
Factors Predicting Relapse in Patients with Genotype 2/3 HCV Treated with Pegylated Interferon plus Ribavirin - 5/06/08
•
Cyclophilin Inhibitor Debio 025 Exhibits Additive Activity against HCV in Combination with Pegylated Interferon - 5/06/08
•
IDEAL Study Finds Higher End-of-treatment Response with Pegasys, but Lower Relapse Rate with PegIntron - 5/02/08
•
Milk Thistle (Silibinin) Shows Potent Antiviral Activity in Hepatitis C Patients Who Are Non-responders to Pegylated Interferon/Ribavirin - 5/02/08
•
R7128 Demonstrates Potent Anti-HCV Activity in Combination with Pegylated Interferon/Ribavirin; Ongoing Trial to be Expanded - 4/29/08
•
Large HCV RNA Decrease Reduces Adverse Clinical Outcomes, but Pegylated Interferon Maintenance Adds Little Benefit (HALT-C) - 4/29/08
•
Pegylated Interferon Maintenance Demonstrates Benefits for Hepatitis C Patients with Portal Hypertension - 4/29/08
•
HCV Polymerase Inhibitor R1626 Produces Good Response with Pegylated Interferon/Ribavirin and Has High Barrier to Resistance - 4/29/08
•
Telaprevir plus Pegylated Interferon and Ribavirin Allows Shorter Therapy for Patients with Genotype 1 HCV - 4/29/08
•
FDA Approves New Weight-Based Dosing Regimen for PegIntron plus Ribavirin - 3/28/08
•
Use of Different Pegylated Interferon/Ribavirin Regimens after Rapid Virological Response Does Not Affect Sustained Response Rate - 3/18/08
•
Pegylated Interferon plus Ribavirin for Patients with HCV-related Liver Cirrhosis - 3/11/08
•
FDA Approves New Weight-Based Dosing Regimen for PegIntron plus Ribavirin - 3/28/08
•
Duration of Pegylated Interferon plus Ribavirin for HCV Genotypes 2 and 3 - 1/29/08
•
Hepatology Expert Discusses PegIntron vs Pegasys IDEAL Study Findings - 1/18/08
•
Growth Hormone Deficiency Common in Hepatitis C Patients, but Improves with Interferon-based Treatment - 1/08/08
•
Pegylated Interferon plus Ribavirin in the Treatment of Chronic Hepatitis C Genotype 4 - 1/08/08
•
Duration of Pegylated Interferon plus Ribavirin May Be Tailored Based on Early Response - 1/04/08
•
Eltrombopag Raises Platelet Counts, Enabling Initiation of Interferon-based Therapy for Hepatitis C - 12/14/07
•
Experimental Polymerase Inhibitor HCV-796 is Safe and Effective in Combination with PegIntron or Pegasys - 12/07/07
•
Depression Due to Treatment with Pegylated Interferon plus Ribavirin May Be Under-diagnosed by Clinicians - 11/30/07
•
How Effective Is Pegylated Interferon plus Ribavirin for HCV Genotype 1 Patients Over Age 50? - 11/30/07
•
Assessment of HCV RNA at Week 4 and Week 12 Optimizes Prediction of Treatment Outcomes in HCV Patients Treated with Pegylated Interferon Alfa-2b (PegIntron) plus Ribavirin - 11/20/07
•
Viral Kinetics Can Quickly Predict Sustained Virological Response in Hepatitis C Patients with Normal ALT Treated with PegIntron plus Ribavirin - 11/20/07
•
European Drug Regulators Approve PegIntron plus Rebetol for Retreating HCV Patients Who Failed Prior Therapy - 11/16/07
•
Treatment with Low-dose Pegylated Interferon Alfa-2b (PegIntron) Does Not Adversely Affect Quality of Life over a 2-year Period: The COPILOT Trial - 11/16/07
•
Rapid Virological Response at Week 4 Is the Best Predictor of Treatment Outcome in Patients with Chronic Hepatitis C - 11/13/07
•
Consensus Interferon Produces Sustained Response in Some Non-responders and Relapsers to Prior Interferon-based Therapy - 11/13/07
•
 Interim Data Show Nitazoxanide (Alinia) Improves Anti-HCV Activity When Added to Pegylated Interferon plus Ribavirin - 11/13/07
•
Early Treatment Is Indicated for Patients with Chronic Hepatitis C Regardless of Body Weight - 11/13/09
•
Highly Sensitive HCV RNA Tests Required to Evaluate Treatment Response and Relapse Rates and to Create Individualized Treatment Strategies for Hepatitis C Patients - 11/13/09
•
Future Studies Should Avoid Combining Genotype 2 and Genotype 3 Patients Due to Lower Response Rate in the Genotype 3 Population - 11/13/09
•
Ultra Rapid Virological Response at Week 2 Predicts Sustained Response in HCV Genotype 3 Patients with High Viral Load: The Get-C Study - 11/06/07
•
Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin in Non-responders to Pegylated Interferon Alfa-2b (PegIntron) plus Ribavirin: Final Results of the REPEAT Trial - 11/06/07
•
Final Results of the Canadian Pegylated Interferon Alfa-2b (PegIntron) Prospective Optimal Weight-based Dosing Response (POWeR) Study - 11/06/07
•
How Ideal Is the IDEAL Trial?

Intron A + Rebetol (interferon alfa-2b + ribavirin)

Articles on Intron A + Rebetol

•
HCV Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment - 1/29/08
•
Interferon-based Therapy Lowers Lymphoma Risk in Hepatitis C Patients - 1/25/08
•
Growth Hormone Deficiency Common in Hepatitis C Patients, but Improves with Interferon-based Treatment - 1/08/08
•
Eltrombopag Raises Platelet Counts, Enabling Initiation of Interferon-based Therapy for Hepatitis C - 12/14/07
•
Long-term Effect of Interferon/Ribavirin on Incidence of Hepatocellular Carcinoma - 8/15/06
•
Thyroid Dysfunction in Chronic Hepatitis C Patients Treated with Interferon/Ribavirin
 - 8/15/06
•
The Effect of Ribavirin on Bone Density in Children with Chronic Hepatitis C Treated with Interferon-Ribavirin - 11/07/05
•
Interferon with Ribavirin Is Safe and Effective for Children with Chronic Hepatitis C - 11/02/05
•
High-dose Induction Therapy with Interferon Alfa-2b (PegIntron) Plus Ribavirin for Treatment of Relapsers or Nonresponders - 9/19/05
•
Normal Gamma-glutamyl Transferase (GGT) Level Is an Independent Predictive Factor of Sustained Virologic Response in HCV Patients Treated with Interferon Alfa and Ribavirin - 8/26/05
•
Suppression of Blood Cell Formation during Chronic Hepatitis C Therapy with Different Interferon Alfa Mono- and Combination Therapy Regimens - 7/15/05
•
Efficacy of Ribavirin Monotherapy Following Combination Therapy with Interferon Alfa-2b (Intron A) and Ribavirin in Patients with Chronic Hepatitis C - 6/10/05
•
Cost-effectiveness of Ribavirin Plus Interferon Alfa-2b (Intron A) for Either Interferon Relapsers or Nonresponders in Chronic Hepatitis C: a Japanese Trial - 3/28/05

Roferon A + Ribavirin (interferon alfa-2a + ribavirin)

Articles on Intron A + Rebetol

•
HCV Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment - 1/29/08
•
Interferon-based Therapy Lowers Lymphoma Risk in Hepatitis C Patients - 1/25/08
•
Growth Hormone Deficiency Common in Hepatitis C Patients, but Improves with Interferon-based Treatment - 1/08/08
•
Eltrombopag Raises Platelet Counts, Enabling Initiation of Interferon-based Therapy for Hepatitis C - 12/14/07
•
Is Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin Superior to High-dose Consensus Interferon (Infergen) plus Ribavirin? - 11/27/07
•
Long-term Effect of Interferon/Ribavirin on Incidence of Hepatocellular Carcinoma - 8/15/06
•
Thyroid Dysfunction in Chronic Hepatitis C Patients Treated with Interferon/Ribavirin
 - 8/15/06
•
Normal Gamma-glutamyl Transferase (GGT) Level Is an Independent Predictive Factor of Sustained Virologic Response in HCV Patients Treated with Interferon Alfa and Ribavirin - 8/26/05
•
 Regression of Lymphoproliferative Disorders after Treatment for Hepatitis C Infection - 3/25/05
•
24-weeks Retreatment of Chronic Hepatitis C Nonresponders to Interferon Alfa Monotherapy - 3/21/05
•
Combination Antiviral Treatment Is Safe and Effective in Non-organ-specific Autoantibodies Positive Individuals with Chronic Hepatitis C - 1/31/05